All In Biotech

Drug Trial Radar · NCT05489055

Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA

Department of Radiology

Last checked: Nov 19, 2026Latest source record: Aug 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Feb 1, 2022

Primary completion

Jan 1, 2023

Study completion Feb 28, 2023

Sponsor

Lead sponsor
Chongqing Emergency Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Army Medical Center of PLA
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extrinsic prewarming of iodinated CT contrast media (CM) to body temperature reduces viscosity and injection pressures. However, guideline recommendations on the necessity to prewarm iodinated CM are conflicting. And studies examining the effect of extrinsic warming CM for coronary CTA(CCTA) on clinical adverse events and image quality are lack. Enrolled patients of chest pain or coronary artery disease screening were eligible for this a double-blinded, randomized noninferiority trial, and equally allocated into two group randomly: BBT-CM (basic body temperature) group received 37°C CM; RT-CM (room temperature) group received \~23°C CM. A state-of-the-art individualized CM (iopamidol at 370 mg I/mL) injection protocol was used, based on body weight.

Conditions

  • Contrast Media Adverse Reaction

Interventions

  • IopamidolDrug

    A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a flow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vessel AttenuationTime frame: Expected within one month after the coronary CTA is performed

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chongqing Emergency Mediacl Centre

    Chongqing, Chonqing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.